DJIA 16,654.77 369.26 2.27%
NASDAQ 4,812.71 115.17 2.45%
S&P 500 1,987.66 47.15 2.43%
market minute promo

Isis Pharmaceuticals (NASDAQ: ISIS)

51.56 2.54 (5.18%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

ISIS $51.56 5.18%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $49.74
Previous Close $49.02
Daily Range $49.33 - $51.91
52-Week Range $35.26 - $77.80
Market Cap $6.2B
P/E Ratio 258.00
Dividend (Yield) $0.00 (0.0%)
Volume 2,186,462
Average Daily Volume 1,741,766
Current FY EPS -$0.52

Sector

Healthcare

Industry

Drug Makers

Isis Pharmaceuticals (ISIS) Description

The Company is a biopharmaceutical company exploiting proprietary RNA-based drug discovery technologies to create a new class of drugs to treat important diseases. Website: http://www.isispharm.com/

News & Commentary

Isis' News-Filled Week

The biotech announces a new partnership, clinical trial results, and earnings over the course of two days.

5 Top BioPharma Stocks That May Have Sold Off Too Much and Become Bargains

3 Promising Biotechs Hobbled By First-Impression Issues

Isis Pharmaceuticals Enters Oversold Territory (ISIS)

Isis Pharmaceuticals Misses on Q2 Earnings and Revenues - Analyst Blog

Isis Pharmaceuticals Misses on Q2 Earnings and Revenues - Analyst Blog

Isis Pharmaceuticals (ISIS) Earnings Report: Q2 2015 Conference Call Transcript

Isis Pharmaceuticals' (ISIS) CEO Stan Crooke on Q2 2015 Results - Earnings Call Transcript

Isis Pharmaceuticals (ISIS) Misses Earnings Estimates in Q2 - Tale of the Tape

Will Isis Pharmaceuticals (ISIS) Beat Q2 Earnings Estimates? - Analyst Blog

Isis Pharma 8-K Filing Shows Company Enters Agreement with Astrazeneca To Discover And Develop Antis

Isis Pharma 8-K Filing Shows Company Enters Agreement with Astrazeneca To Discover And Develop Antisense Drugs FOr Cardiovascular, Metabolic And Renal Disease

See More ISIS News...

ISIS's Top Competitors

ISIS $51.56 (5.18%)
Current stock: ISIS
AMGN $155.72 (1.13%)
Current stock: AMGN
GILD $107.99 (0.96%)
Current stock: GILD
BIIB $304.49 (2.09%)
Current stock: BIIB